
Add to Cart
SARS-CoV-2 Vaccine (Vero cell), Inactivated Novel Coronavirus Vaccine
Our History &Products
We focuses on the Research, Development, Manufacture and Commercialization
of vaccines for infectious diseases with significant unmet medical need.
Worldwide Market & Footprint
The cumulative global sales are nearly 160 million doses. In 2019, an average of 112 people per minute were vaccinated with Sinovac’s
vaccines to obtain immune protection.
Sinovac’s vaccine has been sold in 22 countries around the world, has been registered in 17 countries, and is being registered in 26
countries, covering 3.25 billion people 68 million newborns
The hepatitis A vaccine Healive® ® is the first HepA vaccine in China to pass WHO-PQ, and is being exported to more than 10 “Belt and
Road” countries and international organizations such as UNICEF and PAHO.